Thyrocare Technologies Ltd
Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.
- Market Cap ₹ 8,678 Cr.
- Current Price ₹ 545
- High / Low ₹ 578 / 340
- Stock P/E 54.0
- Book Value ₹ 36.8
- Dividend Yield 1.71 %
- ROCE 35.4 %
- ROE 28.4 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 131%
Cons
- Stock is trading at 14.8 times its book value
- Promoters have pledged 100% of their holding.
- Promoter holding has decreased over last 3 years: -10.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 183 | 241 | 304 | 356 | 403 | 434 | 495 | 589 | 527 | 572 | 687 | 829 | |
| 110 | 147 | 189 | 212 | 249 | 261 | 323 | 353 | 403 | 432 | 498 | 566 | |
| Operating Profit | 73 | 94 | 115 | 145 | 154 | 174 | 171 | 236 | 123 | 140 | 190 | 263 |
| OPM % | 40% | 39% | 38% | 41% | 38% | 40% | 35% | 40% | 23% | 24% | 28% | 32% |
| 8 | 7 | -15 | 21 | 11 | 1 | 12 | 29 | 9 | 9 | 15 | 12 | |
| Interest | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 3 | 5 | 6 | 4 | 4 |
| Depreciation | 13 | 18 | 18 | 20 | 26 | 32 | 30 | 34 | 39 | 47 | 55 | 59 |
| Profit before tax | 68 | 82 | 82 | 145 | 138 | 140 | 152 | 228 | 89 | 96 | 145 | 213 |
| Tax % | 35% | 37% | 48% | 36% | 38% | 37% | 26% | 23% | 27% | 28% | 38% | 24% |
| 44 | 52 | 43 | 93 | 85 | 88 | 113 | 176 | 64 | 69 | 91 | 163 | |
| EPS in Rs | 2.98 | 3.21 | 2.66 | 5.79 | 5.38 | 5.58 | 7.13 | 11.10 | 4.06 | 4.45 | 5.76 | 10.24 |
| Dividend Payout % | 171% | 104% | 125% | 58% | 124% | 30% | 117% | 45% | 148% | 135% | 122% | 137% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 11% |
| 3 Years: | 16% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 8% |
| 3 Years: | 36% |
| TTM: | 85% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 4% |
| 3 Years: | 45% |
| 1 Year: | 53% |
| Return on Equity | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 20% |
| 3 Years: | 20% |
| Last Year: | 28% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 51 | 54 | 54 | 54 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 159 |
| Reserves | 226 | 312 | 354 | 390 | 382 | 314 | 374 | 474 | 481 | 474 | 494 | 426 |
| 0 | 0 | 0 | 0 | 2 | 12 | 8 | 21 | 23 | 42 | 25 | 51 | |
| 53 | 44 | 30 | 36 | 37 | 90 | 106 | 60 | 74 | 75 | 121 | 111 | |
| Total Liabilities | 329 | 410 | 438 | 479 | 475 | 469 | 541 | 607 | 632 | 644 | 693 | 747 |
| 196 | 259 | 259 | 299 | 294 | 269 | 253 | 285 | 294 | 306 | 297 | 317 | |
| CWIP | 6 | 1 | 17 | 0 | 1 | 5 | 8 | 3 | 2 | 3 | 14 | 3 |
| Investments | 86 | 93 | 104 | 120 | 95 | 90 | 126 | 146 | 144 | 162 | 162 | 177 |
| 42 | 56 | 58 | 60 | 84 | 105 | 154 | 173 | 192 | 173 | 220 | 250 | |
| Total Assets | 329 | 410 | 438 | 479 | 475 | 469 | 541 | 607 | 632 | 644 | 693 | 747 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34 | 68 | 90 | 107 | 100 | 168 | 115 | 113 | 129 | 168 | 180 | 213 | |
| -18 | -18 | -42 | -43 | -12 | 1 | -49 | -24 | -39 | -91 | -41 | -23 | |
| -23 | -45 | -49 | -64 | -94 | -165 | -62 | -89 | -86 | -85 | -130 | -170 | |
| Net Cash Flow | -6 | 5 | -0 | -0 | -5 | 4 | 4 | 0 | 4 | -8 | 8 | 21 |
| Free Cash Flow | 25 | 53 | 53 | 63 | 61 | 158 | 93 | 99 | 88 | 107 | 146 | 198 |
| CFO/OP | 79% | 106% | 113% | 108% | 104% | 122% | 92% | 72% | 128% | 141% | 122% | 104% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 10 | 11 | 8 | 10 | 11 | 14 | 33 | 58 | 59 | 28 | 39 | 33 |
| Inventory Days | 48 | 56 | 65 | 66 | 60 | 64 | 52 | 53 | 62 | 104 | 89 | 81 |
| Days Payable | 5 | 10 | 6 | 25 | 25 | 68 | 56 | 36 | 54 | 88 | 146 | 109 |
| Cash Conversion Cycle | 53 | 57 | 67 | 50 | 46 | 10 | 29 | 75 | 67 | 44 | -18 | 4 |
| Working Capital Days | 28 | 2 | 19 | 10 | 28 | -8 | 19 | 41 | 31 | 7 | 13 | 19 |
| ROCE % | 24% | 28% | 33% | 30% | 35% | 36% | 42% | 17% | 18% | 25% | 35% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tests Conducted Million |
|
|||||||||||
| Patients Served Million |
||||||||||||
| Quarterly Active Franchisees count |
||||||||||||
| Number of Labs (India) count |
||||||||||||
| Average Turnaround Time hours |
||||||||||||
| Revenue per Test INR |
||||||||||||
| Tests per Patient count |
||||||||||||
| Complaints per Million Tests count |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
30 Jun - Members approved MOA amendment at 26th AGM on June 30, 2026, expanding business objects.
-
Change In Statutory Auditors Of The Company
30 Jun - Shareholders approved Price Waterhouse Chartered Accountants LLP as statutory auditor for five years from June 30, 2026.
- Shareholder Meeting / Postal Ballot-Outcome of AGM 30 Jun
- Closure of Trading Window 24 Jun
-
Communication To Shareholders - Intimation On Tax Deduction On Dividend
10 Jun - Thyrocare recommended Rs.7 final dividend for FY26; AGM June 30, 2026, record date June 23, 2026.
Annual reports
-
Financial Year 2026
from bse
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
Concalls
-
May 2026Transcript PPT
-
Feb 2026Transcript PPT REC
-
Oct 2025Transcript PPT
-
Jul 2025Transcript PPT REC
-
Apr 2025Transcript PPT REC
-
Jan 2025Transcript PPT
-
Oct 2024Transcript PPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022TranscriptAI SummaryPPT
-
Nov 2021TranscriptAI SummaryPPT
-
Aug 2021TranscriptAI SummaryPPT
-
May 2021TranscriptAI SummaryPPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Jul 2020TranscriptAI SummaryPPT
-
May 2020TranscriptAI SummaryPPT
-
Feb 2020TranscriptAI SummaryPPT
-
Nov 2019TranscriptAI SummaryPPT
-
Aug 2019TranscriptAI SummaryPPT
-
Jun 2019TranscriptPPT
-
May 2019TranscriptAI SummaryPPT
-
Feb 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018Transcript PPT
-
Feb 2018Transcript PPT
-
Dec 2017Transcript PPT
Business Segments
1) Diagnostic Testing Services (92% in FY25 vs 94% in FY22): [1] [2] The company is one of the leading Pan-India diagnostic chains, offering a range of tests focused on early disease detection and health management. It provides 929 tests and 288 profiles, including 43 wellness packages under the “Aarogyam” brand. It processes 3 Bn investigations annually and can process 10 Bn annually. [3] [4]